The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis.
Wen-Chi WuChi-Cheng HuangYi-Fang TsaiYen-Shu LinChin-Jung FengYen-Jen ChenJiun-I LaiTa-Chung ChaoChun-Yu LiuLing-Ming TsengPublished in: Breast cancer research and treatment (2022)
Trastuzumab in real-world practice was associated with an increased risk of HF, but was not associated with an increased risk of Af in BC patients. Trastuzumab-induced arrhythmogenic effects may be masked by concurrent heart-protecting measures, more prominent roles of comorbidities or concurrent medications under real-world settings. Further studies are required.
Keyphrases
- atrial fibrillation
- heart failure
- clinical practice
- epidermal growth factor receptor
- end stage renal disease
- metastatic breast cancer
- ejection fraction
- chronic kidney disease
- healthcare
- primary care
- newly diagnosed
- locally advanced
- left atrial
- catheter ablation
- prognostic factors
- peritoneal dialysis
- left atrial appendage
- direct oral anticoagulants
- high glucose
- tyrosine kinase
- oxidative stress
- percutaneous coronary intervention
- radiation therapy
- squamous cell carcinoma
- venous thromboembolism
- cardiac resynchronization therapy
- quality improvement
- drug induced
- mitral valve